Embecta Corp. Announces Quarterly Cash Dividend
The Board of Directors of Embecta Corp. (Nasdaq: EMBC) has officially declared a quarterly cash dividend amounting to $0.15 for every share of its common stock outstanding. This dividend is set to be distributed on December 18 to stockholders on record as of December 5.
Future Plans of Embecta Corp.
Embecta is a company with a rich history spanning over a century in insulin delivery. It is steadily moving towards transforming itself into a well-rounded medical supplies provider. This shift is not just an operational change; it embodies the commitment of Embecta to enhance the quality of life for individuals reliant on medical supplies.
A Commitment to Innovation
With approximately 2,000 dedicated employees across the globe, Embecta strives to provide innovative medical solutions. The passion and expertise of these employees are vital in driving the organization forward. By investing in research and development, Embecta is actively working on expanding its product range to accommodate a broader spectrum of medical needs.
Building Strategic Partnerships
Embecta's approach includes establishing strategic collaborations that foster innovation and enhance service delivery. By partnering with other leaders in the medical supply field, Embecta aims to leverage collective resources to develop advanced methodologies that benefit the end-users. These partnerships also play a crucial role in ensuring that Embecta remains at the forefront of the ever-evolving healthcare industry.
Market Position and Commitment to Quality
As it positions itself as a key player in the medical supply space, Embecta remains committed to quality and reliability in its offerings. The recent dividend declaration signifies not only financial stability but also a clear intention to reward stockholders as the company progresses in its strategic initiatives.
Engagement with Communities
Embecta understands the importance of engaging with its community, both in terms of customers and stakeholders. The company's social media presence on platforms such as Facebook, LinkedIn, and Instagram allows it to maintain direct communication with its audience, sharing insights about innovations and corporate developments. This engagement is crucial in building trust and ensuring transparency among its stakeholders.
Contacts for Further Information
For those seeking additional information, Embecta encourages inquiries through its dedicated media and investor relations teams. Christian Glazar, Senior Director of Corporate Communications, and Pravesh Khandelwal, Vice President of Investor Relations, lead these efforts.
Media Inquiries
Contact: Christian Glazar
Phone: 908-821-6922
Investor Relations
Contact: Pravesh Khandelwal
Phone: 551-264-6547
Frequently Asked Questions
What is the amount of the declared cash dividend by Embecta?
The declared cash dividend by Embecta is $0.15 per share of common stock.
When will the dividend be paid?
The dividend will be paid on December 18 to stockholders of record as of December 5.
What is Embecta's legacy in the industry?
Embecta has a legacy of over 100 years in insulin delivery, and it is working towards becoming a broad-based medical supplies company.
How does Embecta engage with its community?
Embecta engages with its community through social media channels and direct communication with stakeholders.
Who can be contacted for media inquiries?
For media inquiries, Christian Glazar, Senior Director of Corporate Communications, can be contacted at 908-821-6922.
